



- Hormone receptor negative
  - Individual has asymptomatic visceral disease
  - Individual has involvement of bone or soft tissue
  - Other
- Faslodex® will be given as subsequent line endocrine therapy (following prior endocrine therapy within one year or progression on another agent)
  - Hormone receptor positive
    - Endocrine therapy refractory
    - Individual has asymptomatic visceral disease
    - Individual has involvement of bone or soft tissue
    - Other
  - Hormone receptor negative
    - Individual has asymptomatic visceral disease
    - Individual has involvement of bone or soft tissue
    - Other
- Other

## (2). Post-Menopausal

- Post-menopausal female with breast cancer (check all that apply)
  - Individual with recurrent disease
  - Individual with metastatic disease
  - Individual with disease progression following anti-estrogen treatment
    - Hormone receptor positive
  - Faslodex® will be given as first line endocrine therapy (no prior endocrine therapy within one year)
    - Hormone receptor positive
    - Endocrine therapy refractory
    - Individual has asymptomatic visceral disease
    - Individual has involvement of bone or soft tissue
    - Other
  - Hormone receptor negative
    - Individual has asymptomatic visceral disease
    - Individual has involvement of bone or soft tissue
    - Other
  - Faslodex® will be given as subsequent line endocrine therapy (following prior endocrine therapy within one year or Progression on another endocrine agent)
    - Hormone receptor positive
      - Endocrine therapy refractory
      - Individual has asymptomatic visceral disease
      - Individual has involvement of bone or soft tissue
      - Other
    - Hormone receptor negative
      - Individual has asymptomatic visceral disease
      - Individual has involvement of bone or soft tissue
      - Other
- Other

## Part B: Breast Cancer in Males

- Male with metastatic or recurrent breast cancer. (If checked, please complete below):
  - Individual is undergoing concomitant suppression of testicular steroidogenesis treatment
    - Faslodex® will be given as first line endocrine therapy (no prior endocrine therapy within one year)
      - Hormone receptor positive
        - Endocrine therapy refractory
        - Individual has asymptomatic visceral disease
        - Individual has involvement of bone or soft tissue
        - Other
      - Hormone receptor negative
        - Individual has asymptomatic visceral disease
        - Individual has involvement of bone or soft tissue
        - Other

- Faslodex® will be given as subsequent line endocrine therapy (following prior endocrine therapy within one year or progression on another endocrine agent)
  - Hormone receptor positive
  - Endocrine therapy refractory
  - Individual has asymptomatic visceral disease
  - Individual has involvement of bone or soft tissue
  - Other
- Hormone receptor negative
  - Individual has asymptomatic visceral disease
  - Individual has involvement of bone or soft tissue
  - Other
- Other

**Part C: Other Use(s)** (Please submit all supporting documents including labs, progress notes, imaging, etc., for review.)

This request is being submitted:

- Pre-Claim
- Post-Claim. If checked, please attach the claim or indicate the claim number \_\_\_\_\_

I attest the information provided is true and accurate to the best of my knowledge. I understand that the health plan or its designees may perform a routine audit and request the medical documentation to verify the accuracy of the information reported on this form.

\_\_\_\_\_  
 Name and Title of Provider or Provider Representative Completing  
 Form and Attestation (Please Print)\*

\_\_\_\_\_  
 Date

**\*The attestation fields must be completed by a provider or provider representative in order for the tool to be accepted.**

Anthem UM Services, Inc., a separate company, is the licensed utilization review agent that performs utilization management services on behalf of your health benefit plan or the administrator of your health benefit plan.